CG Oncology Inc

CGON remains in a Stage 2 advancing corrective reset with higher highs and higher lows intact. Price has recently held above rising short-term EMAs and the 50 DMA on a shallow pullback, setting up a favorable pullback entry under a momentum + EPS strategy. Short-term timing is Bullish, as price tracks above the 9 EMA and 21 EMA with no exhaustion visible. A Buy Now execution targeting the EMA support area is appropriate. The primary risk is a deeper pullback below the EMAs and the 50 DMA, which would invalidate the bullish posture.

• ↑Analysts set $92.50 target, implying 53% upside.
• ↑Lead therapy shows 76% complete response durability.
• ↓Earnings yield is –1.97%, indicating weak profitability.